Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)

4 listopada 2026 zaktualizowane przez: Gilead Sciences

Bezproblemowe pod względem operacyjnym randomizowane, otwarte, wieloośrodkowe badanie z aktywną kontrolą fazy 2/3 w celu oceny bezpieczeństwa i skuteczności biktegrawiru/lenakapawiru w porównaniu ze stabilnym schematem wyjściowym u osób z supresją wirusologiczną z HIV-1 w stabilnych złożonych schematach leczenia

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

689

Faza

  • Faza 2
  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Cape Town, Afryka Południowa, 7925
        • Desmond Tutu Health Foundation Clinical Trials Unit
      • Ga-Rankuwa, Afryka Południowa, 208
        • Sefako Makgatho Health Sciences University
      • Johannesburg, Afryka Południowa, 2193
        • Ezintsha
      • Buenos Aires, Argentyna, 1202
        • Fundación Huésped
      • Buenos Aires, Argentyna, 1072
        • Hospital General de Agudos J.M Ramon Mejia
      • Buenos Aires, Argentyna, 1425
        • Helios Salud
    • New South Wales
      • Darlinghurst, New South Wales, Australia, 2010
        • St.Vincent's Hospital Sydney
      • Darlinghurst, New South Wales, Australia, 2011
        • Taylor Square Private Clinic
      • Sydney, New South Wales, Australia, 2010
        • Holdsworth House Medical Practice
    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Alfred Health
      • Nice, Francja, 6202
        • CHU Nice-Hôpital l'Archet
      • Paris, Francja, 75010
        • Hospital Saint Louis
      • Paris, Francja, 75018
        • Groupe Hospitalier Bichat Claude Bernard
      • Paris, Francja, 75651
        • Höpital de la Pitié Salpêtrière
      • Barcelona, Hiszpania, 08036
        • Hospital Clinic Provincial de Barcelona
      • Madrid, Hiszpania, 28040
        • Hospital Clinico San Carlos
      • Madrid, Hiszpania, 28046
        • Hospital Universitario La Paz
      • Madrid, Hiszpania, 28034
        • Hospital Ramon y Cajal, Madrid
      • Seville, Hiszpania, 4103
        • Hospital Universitario Virgen del Rocio
      • Nagoya, Japonia
        • National Hospital Organization Nagoya Medical Center
      • Osaka, Japonia, 540-0006
        • National Hospital Organization Osaka National Hospital
      • Tokyo, Japonia, 162-0052
        • Center Hospital of the National Center for Global Health and Medicine
      • Decarie Montreal, Kanada, H4A 3J1
        • Chronic Viral Illness Service / McGill University Health Centre (MUHC)
      • Montreal, Kanada, H2L 0B1
        • Clinique Medicale du Quartier Latin
      • Ottawa, Kanada, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Regina, Kanada, S4P 0W5
        • ID Clinic
      • Toronto, Kanada, M5G 1K2
        • Maple Leaf Research
      • Vancouver, Kanada, V6Z 2T1
        • Spectrum Health
      • Daegu, Korea Południowa, 41944
        • Kyungpook National University Hospital
      • Daejeon, Korea Południowa, 35015
        • Chungnam National University Hospital
      • Seoul, Korea Południowa, 06591
        • The Catholic University of Korea Seoul St. Mary's Hospital
      • Seoul, Korea Południowa, 03722
        • Yonsei University Severance Hospital
      • Berlin, Niemcy, 10439
        • zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
      • Bonn, Niemcy, 53127
        • Universitatsklinikum Bonn
      • Frankfurt, Niemcy, 60596
        • Infektio Research GmbH & Co.KG
      • Hamburg, Niemcy, 20146
        • ICH Study Center GmbH & Co. KG
      • München, Niemcy
        • MVZ München am Goetheplatz
    • PR
      • San Juan, PR, Portoryko, 00909
        • Hope Clinical Research
      • San Juan, PR, Portoryko, 00935
        • Proyecto ACTU
      • Santo Domingo, Republika Dominikany
        • Instituto Dominicano de Estudio Virologicos - IDEV
    • California
      • Berkeley, California, Stany Zjednoczone, 48072
        • Be Well Medical Center
      • Beverly Hills, California, Stany Zjednoczone, 90211
        • Pacific Oaks Medical Group
      • Los Angeles, California, Stany Zjednoczone, 90036
        • Ruane Clinical Research Group, Inc
      • Oakland, California, Stany Zjednoczone, 94609
        • Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
      • Palm Springs, California, Stany Zjednoczone, 92262
        • Bios Clinical Research
      • San Diego, California, Stany Zjednoczone, 92103
        • University of California San Diego (UCSD)
      • Torrance, California, Stany Zjednoczone, 90502
        • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
      • West Hollywood, California, Stany Zjednoczone, 90046
        • The Men's Health Foundation
    • Colorado
      • Denver, Colorado, Stany Zjednoczone, 80204
        • Denver Health Medical Center
    • Connecticut
      • New Haven, Connecticut, Stany Zjednoczone, 06510
        • Yale University; School of Medicine; AIDS Program
    • Florida
      • DeLand, Florida, Stany Zjednoczone, 32720
        • Midland Florida Clinical Research Center, LLC
      • Fort Lauderdale, Florida, Stany Zjednoczone, 33316
        • Gary Richmond, MD, PA, Inc.
      • Fort Lauderdale, Florida, Stany Zjednoczone, 33308
        • Therafirst Medical Centers
      • Ft. Pierce, Florida, Stany Zjednoczone, 34982
        • Midway Immunology & Research Center, LLC
      • Miami, Florida, Stany Zjednoczone, 33136
        • Schiff Center for liver Diseases/University of Miami
      • Miami Lakes, Florida, Stany Zjednoczone, 33016
        • Floridian Clinical Research
      • Orlando, Florida, Stany Zjednoczone, 32803
        • Orlando Immunology Center
      • Orlando, Florida, Stany Zjednoczone, 32803
        • Therapeutic Concepts, PA
      • West Palm Beach, Florida, Stany Zjednoczone, 33407
        • Triple O Research Institute PA
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30309
        • Atlanta ID Group
      • Macon, Georgia, Stany Zjednoczone, 31201
        • Mercer University School of Medicine
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60613
        • Howard Brown Health Center
    • Missouri
      • Kansas City, Missouri, Stany Zjednoczone, 64111
        • Kansas City Care Clinic
      • St Louis, Missouri, Stany Zjednoczone, 63139
        • Southampton Healthcare, Inc.
    • New Jersey
      • Newark, New Jersey, Stany Zjednoczone, 07102
        • Saint Michael's Medical Center
    • New Mexico
      • Santa Fe, New Mexico, Stany Zjednoczone, 87505
        • AXCES Research Group
    • New York
      • Flushing, New York, Stany Zjednoczone, 11355
        • New York Presbyterian Hospital
      • New York, New York, Stany Zjednoczone, 10001
        • Ricky K. Hsu, MD, PC
    • North Carolina
      • Chapel Hill, North Carolina, Stany Zjednoczone, 27514
        • University of North Carolina - Chapel Hill
      • Greenville, North Carolina, Stany Zjednoczone, 27858
        • East Carolina University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19107
        • Philadelphia FIGHT
    • South Carolina
      • Charleston, South Carolina, Stany Zjednoczone, 29425
        • Medical University of South Carolina (MUSC) Research NEXUS
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78705
        • Central Texas Clinical Research
      • Bellaire, Texas, Stany Zjednoczone, 77401
        • St. Hope Foundation
      • Dallas, Texas, Stany Zjednoczone, 75246
        • North Texas Infectious Diseases Consultants
      • Dallas, Texas, Stany Zjednoczone, 75208
        • AIDS Arms, Inc., DBA Prism Health North Texas
      • Fort Worth, Texas, Stany Zjednoczone, 76104
        • Texas Centers for Infectious Disease Associates
      • Houston, Texas, Stany Zjednoczone, 77098
        • Gordon E. Crofoot MD PA
      • Longview, Texas, Stany Zjednoczone, 75605
        • Diagnostic Clinic of Longview - Center for Clinical Research
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98104
        • Peter Shalit, MD
      • Kaohsiung City, Tajwan, 80756
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Kaohsiung City, Tajwan, 81362
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, Tajwan, 22060
        • Far Eastern Memorial Hospital
      • Taoyuan City, Tajwan, 33004
        • Taoyuan General Hospital
      • Milan, Włochy, 20157
        • ASST Fatebenefratelli Sacco
      • Milan, Włochy, 20127
        • IRCCS Ospedale San Raffaele
      • Modena, Włochy, 40124
        • Azienda Ospedaliero-Universitaria di Modena
      • Roma, Włochy, 00149
        • Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
      • Torino, Włochy, 10149
        • ASL Città di Torino
      • Birmingham, Zjednoczone Królestwo, B9 5SS
        • Department of HIV & Sexual Medicine
      • Brighton, Zjednoczone Królestwo, BN2 3EW
        • Brighton and Sussex University Hospitals NHS Trust
      • London, Zjednoczone Królestwo, E1 1BB.
        • Barts Health NHS Trust
      • London, Zjednoczone Królestwo, SE5 9RS
        • HIV medicine and infectious diseases
      • London, Zjednoczone Królestwo, SW109NH
        • St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Key Inclusion Criteria:

  • If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.

  • At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL

  • Plasma HIV-1 RNA levels < 50 copies/mL at screening.

  • Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:

    • A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
    • A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
    • A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
  • No documented or suspected resistance to bictegravir (BIC).

  • Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.

Key Exclusion Criteria:

  • Prior use of, or exposure to, lenacapavir (LEN)
  • Active tuberculosis infection
  • Chronic hepatitis B virus (HBV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg

Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1.

Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP)

Tablets administered orally without regard to food

Inne nazwy:
  • GS-6207

Tablets administered orally without regard to food

Inne nazwy:
  • GS-9883
Eksperymentalny: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg

Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Inne nazwy:
  • GS-6207

Tablets administered orally without regard to food

Inne nazwy:
  • GS-9883
Aktywny komparator: Phase 2: Treatment Group 3: SBR

Participants will continue with their SBR for up to 24 weeks.

Participants who discontinue early or complete the RP will have an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Eksperymentalny: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC

Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Inne nazwy:
  • Bixlenvo™
Aktywny komparator: Phase 3: Treatment Group 2: SBR

Participants will continue with their SBR for up to 48 weeks.

Participants who will discontinue early or complete the RP had an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Eksperymentalny: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC

At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP).

Tablets administered orally without regard to food

Inne nazwy:
  • GS-6207

Tablets administered orally without regard to food

Inne nazwy:
  • Bixlenvo™

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Ramy czasowe: Week 24

Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Ramy czasowe: Week 48

Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

Week 48

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
Ramy czasowe: Week 24

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Ramy czasowe: Baseline, Week 24
Baseline, Week 24
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
Ramy czasowe: First dose date up to Week 24

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

First dose date up to Week 24
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
Ramy czasowe: At Week 16 or 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
Ramy czasowe: At Week 16 or Week 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: AUCtau of BIC at Steady State
Ramy czasowe: At Week 16 or 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: AUCtau for LEN at Steady State
Ramy czasowe: At Week 16 or Week 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of BIC at Steady State
Ramy czasowe: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of LEN at Steady State
Ramy czasowe: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Ramy czasowe: Week 48

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).

Week 48
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
Ramy czasowe: Baseline, Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

Baseline, Week 48
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
Ramy czasowe: First dose date up to Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

First dose date up to Week 48
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Ramy czasowe: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Ramy czasowe: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Ramy czasowe: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Ramy czasowe: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Ramy czasowe: Baseline, Week 96
Baseline, Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Ramy czasowe: Baseline, Week 144
Baseline, Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Ramy czasowe: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Ramy czasowe: Week 144
Week 144

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

16 sierpnia 2022

Zakończenie podstawowe (Rzeczywisty)

29 września 2025

Ukończenie studiów (Szacowany)

1 grudnia 2029

Daty rejestracji na studia

Pierwszy przesłany

5 sierpnia 2022

Pierwszy przesłany, który spełnia kryteria kontroli jakości

12 sierpnia 2022

Pierwszy wysłany (Rzeczywisty)

16 sierpnia 2022

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

4 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • GS-US-621-6289
  • 2022-500929-33 (Inny identyfikator: European Medicines Agency)
  • DOH-27-052023-8574 (Inny identyfikator: South African Clinical Trial Registry)
  • jRCT2051230168 (Inny identyfikator: Japan registry)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj